Milestone Pharmaceuticals Azioni (NASDAQ: MIST)

Ultime notizie per Milestone Pharmaceuticals (NASDAQ:MIST) Azioni

Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals Inc

Mist

MISTRAS Group Inc

Mister Car Wash Inc

Mistico Acquisition Corp

BTIG analyst Clark Lampen maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Buy and raises the price target from $202 to $291.

News

Price Target

Analyst Ratings

BTIG Maintains Buy on AppLovin, Raises Price Target to $291

WIIM

Albemarle shares are trading higher. The company reported Q3 financial results.

Zillow Group, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) shares are trading higher. <a href="https://www.benzinga.com/news/earnings/24/11/41791923/zillow-stock-jumps-on-q3-earnings-revenue-beat-eps-beat-visits-up-3-233m-monthly-active-users">The company reported earnings and investors positively reacted. </a>Estimates for the earnings were 29 cents and came in at 35 cents. Revenue was $581 million versus estimates of $555 million.
Our team of technical analysts made Zillow our Stock of the Day because it illustrates a common dynamic in the market that savvy traders use to profit.
As you can see on the chart, in February and early March levels around $58.50 were resistance for the stock. In September this resistance was broken. Then the stock eventually fell back to the $58.50 level that was previously resistance converted into support.
The same thing happened at the $53.70 level. It was resistance in July and converted to support at the beginning of September.
At the end of September, the $68.40 level was resistance — and now it has become a support level.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="524" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07135700/Zillow.Noc_.2024-1024x524.png" alt="" class="wp-image-636121" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07135700/Zillow.Noc_.2024-1024x524.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07135700/Zillow.Noc_.2024-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07135700/Zillow.Noc_.2024-768x393.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07135700/Zillow.Noc_.2024-1536x786.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07135700/Zillow.Noc_.2024.png 1585w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41814670/donald-trumps-win-coupled-with-macro-factors-sets-stage-for-accelerated-cycle-in-crypto-ma">Donald Trump&#8217;s Win Coupled With Macro Factors Sets Stage For &#8216;Accelerated Cycle&#8217; In Crypto Markets, Analyst Predicts</a>
Price levels resistant converting into support is a common occurrence in not just the stock markets, but in all financial markets.
It happens because of &#8220;seller's remorse.&#8221;
There are investors and traders who sell while the stock is at resistance who think they made a good decision if the price trends lower after. But if the trend reverses, the resistance is broken and the price moves higher, many who sold come to regret their decision to do so.
Some of these remorseful sellers vow to buy their shares back.
But they will only do so if they can buy them for the same price they were sold. So as a result, if the stock eventually falls back to the selling price they place buy orders.
If there are enough of these orders it will cause support to form at the price that had previously been resistance.
If a stock is trending lower and a trader is looking for insight into where to buy it, they should look at price levels that had previously been resistance. There is a good chance the stock finds support at them. They may even reverse and rally.
Read Next: • <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41814589/why-trumps-boost-to-treasury-yields-inflation-expectations-may-weaken-feds-efforts-">Why Trump&#8217;s Boost To Treasury Yields, Inflation Expectations May Weaken Fed&#8217;s Efforts To Cut Interest Rates</a>
Photo: Shutterstock

Technicals

Trading Ideas

Real Estate

Stock Of The Day: Why Would Resistance For Zillow Turn Into Support?

Starting in 2025, students at the California Institute of Integral Studies (CIIS) in San Francisco will be able to pursue a unique academic path: a bachelor's degree in psychedelics studies. This marks the first time an accredited institution in the United States has offered an undergraduate degree focused on <a href="https://www.benzinga.com/markets/psychedelics">hallucinogenic drugs</a>. As The San Francisco Standard <a href="https://sfstandard.com/2024/11/06/psychedelic-major-degree-undergraduate-ciis/">reported</a>, the program aims to prepare students for careers in <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic therapy</a>, integrating psychology, anthropology and neuroscience to explore psychedelics&#8217; role in therapy and society.
Nick Walker, a psychology professor at CIIS who helped design the curriculum, described the program as the result of years of development. "We have incorporated psychology, cultural anthropology, neuroscience, a lot of different angles," Walker explained. One module explores the history of hallucinogens, including <a href="https://www.benzinga.com/markets/cannabis/23/04/31704770/exclusive-the-importance-of-attaining-a-decolonized-perspective-of-psychedelics-therapy">colonialism&#8217;s impact</a> on psychedelics tourism, reflecting the program&#8217;s interdisciplinary approach. CIIS aims to give students a broader, more nuanced understanding of psychedelics beyond recreation.
<h3 class="wp-block-heading">A Response To Growing Demand In Psychedelic Therapy</h3>
The new degree comes amid a <a href="https://www.benzinga.com/markets/cannabis/24/11/41761516/americans-favor-psilocybin-for-mental-health-treatment-study-finds">broader wave of interest in psychedelic therapies</a>, which have shown promise in treating conditions like depression, PTSD and addiction. As <a href="https://www.benzinga.com/topic/psychedelics-research">researchers continue to publish promising results</a>, the market for psychedelic therapies is <a href="https://www.benzinga.com/markets/cannabis/24/10/41589487/global-psychedelic-drugs-market-expected-to-reach-10-2b-by-2028-amid-growing-mental-health-crise">expected to exceed $4.6 billion by 2030</a>, driving a need for professionals trained in the therapeutic application of these substances.
Until now, CIIS and other universities like Berkeley and Columbia have <a href="https://www.benzinga.com/markets/cannabis/24/02/37394447/beckley-academys-open-source-psychedelic-therapy-learning-framework-is-out-whats-it-all-about-au">offered certification programs</a>, but these have been limited to medical professionals and licensed therapists. This new undergraduate program, however, will introduce students to psychedelic studies without the need for previous clinical experience.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41814007/pro-golfers-turn-to-psychedelics-for-focus-boost-and-anxiety-relief">Pro Golfers Turn To Psychedelics For Focus Boost And Anxiety Relief</a>
<h3 class="wp-block-heading">Ethics And Boundaries In Psychedelic Studies</h3>
Ethical considerations are central to CIIS's approach. The curriculum includes immersive experiences and role-playing to help students understand altered states without direct drug use. "This is the first Bachelor of Science in psychedelic studies. That's what the diplomas will say," Walker said. However, he emphasized that the degree is not a professional training program in psychedelic therapy. "If they want to be a psychedelic-assisted therapist, they're going to have to go to grad school and get licensed."
Following past controversies, CIIS has strengthened ethical standards. After a 2021 <a href="https://www.thecut.com/2021/11/cover-story-podcast-goes-into-world-of-psychedelic-therapy.html">podcast</a> exposed alleged misconduct by instructors in psychedelic-assisted therapy, CIIS terminated their contracts and now requires faculty and students to sign an integrity agreement prohibiting romantic relationships with clients. While the scandal wasn&#8217;t directly addressed at the program&#8217;s launch, the importance of consent in therapy was emphasized.&nbsp;
"Touch in psychedelic psychotherapy is really cutting edge, but it's high risk, high reward," said CIIS psychology professor Jason Butler, a panelist at the launch event and <a href="https://www.benzinga.com/topic/ketamine-therapy">ketamine-assisted therapy</a> specialist. "A number of ethical violations have surfaced. … We need to talk about consent before any psychedelic medicine is ingested."
<h3 class="wp-block-heading">Expanding Offerings in Psychedelic Therapy Training</h3>
The new CIIS degree program is not the only new development on the horizon. In 2025, the institute will also launch a ketamine-assisted therapy clinic staffed by graduate students who are licensed clinicians. The clinic will offer supervised experience in ketamine-assisted psychotherapy, a booming treatment in mental health care.
As Walker summarized, "Whatever our graduates end up doing, we hope they'll bring with them high levels of understanding, cultural humility, intellectual curiosity, critical thinking, and ethical integrity."
Cover image made with AI

Cannabis

Psychedelics

Education

California College Launches Nation's First Psychedelic Studies Degree For Undergraduates

Craig-Hallum analyst Anthony Stoss maintains Digital Turbine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPS#NASDAQ">APPS</a>) with a Buy and lowers the price target from $5 to $4.

APPS

Craig-Hallum Maintains Buy on Digital Turbine, Lowers Price Target to $4

Steris shares are trading lower after the company reported worse-than-expected Q2 revenue results

DA Davidson analyst Michael Baker maintains A-Mark Precious Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRK#NASDAQ">AMRK</a>) with a Buy and lowers the price target from $52 to $43.

AMRK

DA Davidson Maintains Buy on A-Mark Precious Metals, Lowers Price Target to $43

The Federal Reserve lowered interest rates by 0.25 percentage points on Thursday, as widely anticipated by the market, bringing the federal funds rate to a target range of 4.5% to 4.75%, the <a href="https://www.benzinga.com/topic/interest-rates">lowest since February 2023. </a>
With this decision, the Fed slowed the pace of rate cuts compared to September, when policymakers opted for a more substantial 0.5% cut to initiate the easing cycle.
The Fed's November policy statement continued to highlight that the economy has expanded at a &#8220;solid pace,&#8221; job growth &#8220;has generally eased&#8221; and inflation &#8220;has made further progress&#8221; toward the 2% target, although it remains &#8220;somewhat elevated.&#8221;
The Personal Consumption Expenditure (PCE) inflation rate eased to 2.1% year-over-year in September 2024, marking its smallest increase since February 2021. The Fed&#8217;s preferred inflation measure, the core PCE price index, which excludes food and energy, remained steady at 2.7%.
Yet the November statement surprisingly omitted a line from September that stated: &#8220;The Committee has gained greater confidence that inflation is moving sustainably toward 2 percent and judges that the risks to achieving its employment and inflation goals are roughly in balance.&#8221;
The Fed reiterated a data-driven approach and highlighted the need to monitor economic implications for future policy decisions, refraining from committing to a predetermined path.
The next Federal Open Market Committee (FOMC) meeting is scheduled for December 18, 2024.
Financial markets are placing a 66% probability on another 25-basis-point cut at the year's final meeting, as per CME FedWatch, though expectations have dropped significantly following this week&#8217;s election results.
Market attention now shifts to Fed Chair Jerome Powell's press conference at 2:30 p.m. ET. 
Powell is expected to face questions on potential inflationary pressures from Trump&#8217;s trade tariffs and anticipated higher budget deficits and how the Fed might respond to changes in the <a href="https://www.benzinga.com/markets/equities/24/11/41785495/us-treasuries-take-sharpest-plunge-in-a-year-ahead-of-fed-meeting-could-powell-adjust-stance-in-">economic and political landscape</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41814589/why-trumps-boost-to-treasury-yields-inflation-expectations-may-weaken-feds-efforts-">Why Trump&#8217;s Boost To Treasury Yields, Inflation Expectations May Weaken Fed&#8217;s Efforts To Cut Interest Rates</a></li>
</ul>
Illustration of Federal Reserve Chair Jerome Powell created using artificial intelligence via MidJourney.

Macro Economic Events

Econ #s

Economics

Federal Reserve

Fed Cuts Interest Rates To Lowest Since February 2023, Sticks To Data-Driven Path

Craig-Hallum analyst Jeff Van Rhee maintains Fastly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) with a Hold and raises the price target from $6 to $8.

FSLY

Craig-Hallum Maintains Hold on Fastly, Raises Price Target to $8

DA Davidson analyst Tom White maintains Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) with a Buy and raises the price target from $71 to $75.

DA Davidson Maintains Buy on Zillow Gr, Raises Price Target to $75

FBIN

Fortune Brands shares are trading lower after the company reported worse-than-expected Q3 revenue results and cut its FY24 guidance. Multiple firms lowered their respective price targets on the stock.

Bernstein analyst Stacy Rasgon maintains Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) with a Outperform and raises the price target from $200 to $215.

QCOM

Bernstein Maintains Outperform on Qualcomm, Raises Price Target to $215

DA Davidson analyst Rudy Kessinger maintains Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) with a Neutral and raises the price target from $35 to $39.

DA Davidson Maintains Neutral on Rapid7, Raises Price Target to $39

DBGI

Digital Brands Group Repays All Convertible Debt Securities, Extinguishing Obligations Under Securities Purchase Agreements; Announces Debt-Free Status In Press Release

Craig-Hallum analyst Greg Palm maintains Faro Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) with a Buy and raises the price target from $25 to $30.

FARO

Craig-Hallum Maintains Buy on Faro Technologies, Raises Price Target to $30

Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) stock hit a new 52-week high on Thursday after the company reported better-than-expected financial results and raised its full-year guidance above estimates. Here&#8217;s what <a href="https://www.benzinga.com/news/earnings/24/11/41791482/dutch-bros-stock-perks-up-after-solid-q3-earnings-report-details">you need to know</a>. 
The Details: Dutch Bros stock soared about 15% after the market closed on Wednesday following the release of the company&#8217;s third-quarter earnings, which included adjusted earnings per share of 16 cents, beating analyst estimates of 12 cents.
In addition, the company reported sales of $338.21 million, beating analyst estimates of $325.14 million. Dutch Bros&#8217; top-line results were up about 28% year-over-year. The company also reported company-operated shop revenues of $308.3 million, representing a 30% year-over-year increase.
The company reported adjusted EBITDA of $63.8 million, compared to $53 million in the same period last year. Dutch Bros also reported adjusted selling, general and administrative expenses totaling $57.5 million.
Throughout the third quarter, Dutch Bros opened 38 new stores across 11 states with 33 of those stores being company-operated.
&#8220;We believe our refined real estate strategy is working, as we are seeing strong new shop productivity as we have shifted our development focus and elevated our site selection process,&#8221; said Dutch Bros CEO Christine Barone.
&#8220;We continue to demonstrate remarkable consistency in our shop opening cadence with 38 shop openings in the&nbsp;third quarter. We are making major investments in our development and construction teams and our 2025 pipeline is strong, positioning us to accelerate new shop growth.&#8221;
Dutch Bros also raised its guidance for the full year above estimates. The company now expects revenue between $1.25 billion and $1.26 billion, versus analyst estimates of $1.23 billion. Dutch Bros previously guided for revenue of $1.21 billion to $1.23 billion.
Additionally, Dutch Bros said it expects adjusted EBITDA of $215 million to $220 million, up from its prior outlook of $200 million to $210 million.
See Also:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41792455/jpmorgan-bank-of-america-and-wells-fargo-shares-surged-wednesday-heres-why"> JPMorgan, Bank Of America And Wells Fargo Shares Surged Wednesday: Here&#8217;s Why</a>
Analyst Changes: Following the earnings report, multiple analysts issued price target adjustments.
<ul>
<li>TD Cowen analyst Andrew Charles maintained a Buy rating on Dutch Bros and raised the price target from&nbsp;$47&nbsp;to&nbsp;$53.</li>
<li>Wedbush analyst Nick Setyan maintained an Outperform rating on Dutch Bros and raised the price target from $45 to $55.</li>
<li>UBS analyst Dennis Geiger maintained a Buy rating on Dutch Bros and raised the price target from&nbsp;$39&nbsp;to&nbsp;$44.</li>
<li>Baird analyst David Tarantino maintained a Neutral rating on Dutch Bros and raised the price target from $37 to $46.</li>
<li>JPMorgan analyst John Ivankoe maintained an Overweight rating and raised the price target from $44 to $48.</li>
</ul>
BROS Price Action: At the time of writing, Dutch Bros stock was up 32.7% at $46.38, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Courtesy of Dutch Bros Inc.

Guidance

Movers

BROS

Dutch Bros Stock Hits 52-Week Highs: What's Going On?

Argus Research analyst John Staszak maintains Restaurant Brands Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>) with a Buy and lowers the price target from $85 to $80.

Argus Research Maintains Buy on Restaurant Brands Intl, Lowers Price Target to $80

DA Davidson analyst Rudy Kessinger maintains Fastly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) with a Neutral and raises the price target from $5.5 to $7.5.

DA Davidson Maintains Neutral on Fastly, Raises Price Target to $7.5

On Thursday, Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock is trading higher on mixed third-quarter earnings and a new mpox trial in Africa.
The company reported third-quarter sales of $293.8 million, up 9% year over year, with the management guidance of $265&nbsp;million–$315 million, and missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $297.5 million</a>.
The company reported an adjusted EPS of $1.37, a turnaround from a loss of $1.09 a year ago,&nbsp;beating <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41786475/emergent-biosolutions-reports-third-quarter-2024-financial-results" rel="noreferrer noopener">the consensus of $0.14</a>.
Revenues from Narcan&nbsp;(naloxone HCl) Nasal Spray decreased 33% to $95.3 million, primarily driven by the discontinuation of prescription Narcan&nbsp;due to the launch of over-the-counter Narcan&nbsp;in the third quarter of 2023 and lower Canadian retail sales, partially offset by higher sales of OTC Narcan.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41026819/emergent-biosolutions-confirms-orders-worth-400m-related-to-smallpox-mpox-vaccines" rel="noreferrer noopener">Emergent BioSolutions Confirms Orders Worth $400M Related To Smallpox, Mpox Vaccines</a>
Revenues from Anthrax MCM fell 65% to $11.4 million, and Smallpox MCM sales jumped more than fivefold to $132.7 million.
Guidance: Emergent BioSolutions updated its 2024 revenue guidance from $1.05 billion &#8211; $1.125 billion to $1.065 billion &#8211; $1.125 billion, compared to the consensus of $1.123 billion.
The updated guidance includes commercial product sales of $420&nbsp;million &#8211;&nbsp;$430 million compared to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40226161/vaccine-maker-emergent-biosolutions-expects-deeper-losses-in-2024-stock-sinks" rel="noreferrer noopener">prior guidance of </a>$450 million – $480 million.
MCM Product sales outlook of $510&nbsp;million &#8211; $550 million, compared to $455&nbsp;million – $490 million expected earlier.
Services segment sales are expected to be $105&nbsp;million &#8211; $110 million, lower than the prior range of $120&nbsp;million – $130 million.
The company expects a 2024 net loss of $203 million &#8211; $183 million, compared to the previous loss range of $314 million – $274 million, and an adjusted EBITDA of $180 million &#8211; $200 million compared to previous forecast of $140 million &#8211; $180 million.
Concurrently, Emergent BioSolutions announced that brincidofovir (brand name Tembexa for smallpox treatment) will be included in a trial conducted and sponsored by PANTHER, under the leadership of the Africa Centres for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41789320/emergent-biosolutions-supports-new-clinical-trial-evaluating-the-safety-and-efficacy-of-brincidofo" rel="noreferrer noopener">Disease Control and Prevention</a>.
The study will evaluate the safety and efficacy of brincidofovir in treating mpox virus. The trial is scheduled to begin in the coming weeks in the Democratic Republic of Congo and neighboring countries.
Price Action: EBS stock is up 28.3% at $11.80 at last check Thursday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41816035/ralph-lauren-soars-as-q2-results-outpace-expectations-ceo-eyes-holiday-season-with-raised-revenue-g" target="_blank" rel="noreferrer noopener">Ralph Lauren Soars As Q2 Results Outpace Expectations—CEO Eyes Holiday Season With Raised Revenue Goals</a></li>
</ul>

Biotech

Earnings

Equities

Health Care

General

Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024

DA Davidson analyst Kurt Yinger maintains TopBuild (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>) with a Buy and lowers the price target from $460 to $450.

DA Davidson Maintains Buy on TopBuild, Lowers Price Target to $450

Milestone Pharmaceuticals GAAP EPS of -$0.14

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Milestone Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/mist-stock-quote/">MIST</a>) just reported results for the second quarter of 2024.<ul><li>Milestone Pharmaceuticals reported earnings per share of -14 cents. This was above the analyst estimate for EPS of -19 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/mist-stock-earnings-milestone-pharmaceuticals-for-q2-of-2024/">MIST Stock Earnings: Milestone Pharmaceuticals Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MIST Stock Earnings: Milestone Pharmaceuticals Beats EPS for Q2 2024

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Milestone Pharmaceuticals (MIST – Research Report) today and set a price target of...

Piper Sandler Sticks to Their Buy Rating for Milestone Pharmaceuticals (MIST)

TD Cowen analyst Ritu Baral has maintained their bullish stance on MIST stock, giving a Buy rating on August 9. Ritu Baral has given his Buy rating...

Buy Rating Affirmed for Milestone Pharmaceuticals on Etripamil's Market Potential and Solid Financial Footing

Milestone Pharmaceuticals (MIST – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Tr...

Milestone Pharmaceuticals: A Buy Rating on CARDAMYST's Market Potential and FDA Progress

Milestone wins Buy at Rodman & Renshaw on potential Cardamyst approval

Milestone Pharmaceuticals (MIST) has provided an update. During the 2024 Annual Meeting of Shareholders, the company's shareholders elected new dir...

Milestone Pharmaceuticals Welcomes New Directors and Auditor

TD Cowen analyst Ritu Baral maintained a Buy rating on Milestone Pharmaceuticals (MIST – Research Report) today and set a price target of $9.00. Th...

TD Cowen Sticks to Its Buy Rating for Milestone Pharmaceuticals (MIST)

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Milestone Pharmaceuticals (MIST – Research Report), wi...

Milestone Pharmaceuticals' CARDAMYST: A Game Changer in PSVT Treatment with Significant Market Potential

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Milestone Pharmaceuticals (MIST – Research Report), with a price ta...

Milestone Pharmaceuticals (MIST) Receives a Buy from TD Cowen

MIST

Press Releases

Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference

Milestone Pharmaceuticals to Host KOL Event for Investors "Learnings from the Field: Expert Perspectives on PSVT in the Community Setting" on June 20, 2024

Comments

Milestone Pharmaceuticals

Notizie

Ultime notizie per Milestone Pharmaceuticals (NASDAQ:MIST) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO